Astaxanthin Sensitizes Low SOD2-Expressing GBM Cell Lines to TRAIL Treatment via Pathway Involving Mitochondrial Membrane Depolarization

Abstract

Carotenoids have been suggested to have either anti- or pro-oxidative effects in several cancer cells, and those effects can trigger an unbalanced reactive oxygen species (ROS) production resulting in an apoptotic response. Our study aimed to evaluate the effect of the well-known carotenoid 3, 3′-dihydroxy-β, β’-carotene-4, 4-dione (astaxanthin, AXT) on glioblastoma multiforme (GBM) cells, especially as a pretreatment of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), that was previously shown to increase ROS and to induce apoptosis in cancer cells. We found that AXT by itself did not trigger apoptosis in four investigated GBM cell lines upon a 24 h treatment at various concentrations from 2.5 to 50 µM. However, in U251-MG and T98-MG GBM cells, pretreatment of 2.5 to 10 µM AXT sensitized cells to TRAIL treatment in a statistically significant manner (p < 0.05) while it did not affect CRT-MG and U87-MG GBM cells. We further compared AXT-sensitive U251-MG and -insensitive CRT-MG response to AXT and showed that 5 µM AXT treatment had a beneficial effect on both cell lines, as it enhanced mitochondrial potential and TRAIL treatment had the opposite effect, as it decreased mitochondrial potential. Interestingly, in U251-MG, 5 µM AXT pretreatment to TRAIL-treated cells mitochondrial potential further decreased compared to TRAIL alone cells. In addition, while 25 and 50 ng/mL TRAIL treatment increased ROS for both cell lines, pretreatment of 5 µM AXT induced a significant ROS decrease in CRT-MG (p < 0.05) while less effective in U251-MG. We found that in U251-MG, superoxide dismutase (SOD) 2 expression and enzymatic activity were lower compared to CRT-MG and that overexpression of SOD2 in U251-MG abolished AXT sensitization to TRAIL treatment. Taken together, these results suggest that while AXT acts as an ROS scavenger in GBM cell lines, it also has some role in decreasing mitochondrial potential together with TRAIL in a pathway that can be inhibited by SOD2.

Eco-friendly and safe alternatives for the valorization of shrimp farming waste

“…Astaxanthin treatment for prostate cancer cells for 9 days decreases tumor growth by 38% (Ranga Rao et al 2010 ; Sun et al 2020 ). Similar kinds of results were obtained by McCall et al ( 2018 ) for breast cancer in vitro, Shin et al ( 2022 ) in glioblastoma cell lines, and Kim et al ( 2019 ) in colon cancer cells. The polyunsaturated fatty acid derivatives of shrimps have also been studied for their chemopreventive action in both in vitro and in vivo studies.…”

Antioxidants in brain tumors: current therapeutic significance and future prospects

“…At high concentrations (20-40 μM), it promotes apoptosis in different types of human astroglioma cells; however, at low concentrations (4-8 μM), it causes hormesis by promoting the cell cycle progression through CDK activation and increasing proliferation through the suppression of p53 antitumor protein [213]. In a recent report, hormesis at low doses has been revealed to be associated with the antioxidant properties of astaxanthin, and partly by lowering the mitochondrial membrane potential [214].…”

Marine Compounds, Mitochondria, and Malignancy: A Therapeutic Nexus

“…Astaxanthin (3,3-dihydroxy-β,β′-carotene-4,4-dione), a carotenoid recognized for its powerful antioxidant capacity, has shown to have anticarcinoma properties in numerous cancer cell types via various signaling pathways. In this way, astaxanthin can enhance the level of proapoptotic proteins like Bax/Bad, reduce antiapoptotic proteins, such as Bcl-2, and can decrease the rate of ROS in glioblastoma multiforme cells [ 117 ]. Additionally, cellulose nanocrystals/nanofibrils loaded with astaxanthin nanoemulsion enhanced the production of ROS in L929 and NIH3T3 cells as in vitro models of skin cancer [ 118 ].…”